Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

Velaglucerase alfa is a human β‐glucocerebrosidase approved for Gaucher disease type 1 (GD1) treatment. This report summarizes the 7‐year experience of the now‐completed phase I/II and extension studies of adult GD1 patients who received velaglucerase alfa. Ten patients who completed the 9‐month, ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimran, Ari, Wang, Nan, Ogg, Carol, Crombez, Eric, Cohn, Gabriel M., Elstein, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033020/
https://www.ncbi.nlm.nih.gov/pubmed/25903392
http://dx.doi.org/10.1002/ajh.24040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033020/
https://www.ncbi.nlm.nih.gov/pubmed/25903392
http://dx.doi.org/10.1002/ajh.24040

Ejemplares similares